Features

• A Rapid Test for the Qualitative Detection of NMP22 Nuclear Matrix Protein in human urine
• The NMP22® BladderChek® Test is an in vitro immunoassay intended for the qualitative detection of the nuclear mitotic apparatus protein (NuMA), which is an abundant component of the nuclear matrix proteins, in urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer
• This test is indicated for professional use and prescription home use as an aid in diagnosing and monitoring bladder cancer patients, in conjunction with standard diagnostic procedures
• Each device incorporates colloidal gold particles conjugated to the reporter antibody and a capture monoclonal antibody, immobilized on a membrane; the procedural Control zone contains an immobilized goat anti-mouse IgG-specific antibody